Epilepsies in children, young people and adults

Supplement 1: Methods

NICE guideline NG217

Methods

April 2022

Evidence reviews were developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists
Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2022. All rights reserved. Subject to Notice of rights.

## Contents

### Development of the guideline

- Remit ............................................................................................................. 5
- What this guideline covers ............................................................................. 5
  - Key areas that are covered ........................................................................... 5

### Methods

- Developing the review questions and outcomes ............................................ 6
- Searching for evidence ..................................................................................... 8
  - Scoping search ............................................................................................... 8
  - Systematic literature search .......................................................................... 8
  - Economic systematic literature search .......................................................... 9
- Reviewing research evidence .......................................................................... 9
  - Systematic review process ............................................................................ 9
  - Type of studies and inclusion/exclusion criteria ........................................... 10
- Methods of combining evidence .................................................................. 11
  - Data synthesis for intervention studies ....................................................... 11
  - Data synthesis for prognostic reviews ......................................................... 13
  - Data synthesis for epidemiologic reviews .................................................... 13
- Appraising the quality of evidence ............................................................... 14
  - Intervention studies ...................................................................................... 14
  - Prognostic studies ......................................................................................... 19
  - Epidemiologic reviews .................................................................................. 21
- Reviewing economic evidence ...................................................................... 22
  - Appraising the quality of economic evidence ............................................. 23
- Economic modelling ....................................................................................... 23
  - Cost effectiveness criteria ............................................................................ 24
- Developing recommendations ..................................................................... 24
  - Guideline recommendations ....................................................................... 24
  - Research recommendations ......................................................................... 25
- Validation process ......................................................................................... 25
- Updating the guideline .................................................................................. 25
- Funding ........................................................................................................... 25

### References .................................................................................................. 26
Development of the guideline

Remit

The National Institute for Health and Care Excellence (NICE) commissioned the National Guideline Alliance (NGA) to develop a guideline on epilepsies in children, young people and adults.

What this guideline covers

Key areas that are covered

Children, young people and adults

- Diagnosis and assessment of epilepsy
- Information and support needs
- Pharmacological management (monotherapy or add-on) of epileptic seizures and epilepsy syndromes
- Pharmacological management (monotherapy or add-on) of epileptic seizures and epilepsy syndromes in girls and women who are able to get pregnant (including those who are pregnant or breastfeeding)
- Non-pharmacological management of epileptic seizures
- Ongoing monitoring, including referral to specialist services and antiseizure medication withdrawal
- Psychological, neurodevelopmental, cognitive and behavioural comorbidities in epilepsy
- Reducing the risk of epilepsy-related mortality
- Service design and delivery
- Transition from children’s and young people’s services to adult’s services

Children and young people only

- Pharmacological management (monotherapy or add-on) of childhood-onset epileptic seizures and epilepsy syndromes

For further details of what the guideline does and does not cover see the guideline scope on the NICE website.
Methods

This guideline was developed using the methods and process described in Developing NICE guidelines: the manual. Declarations of interest were recorded according to the NICE’s conflicts of interest policy.

Developing the review questions and outcomes

The review questions developed for this guideline were based on the key areas identified in the guideline scope. They were drafted by the NGA technical team, and refined and validated by the guideline committee. The methods outlined in this supplement are relevant for the review questions in Table 1 only.

The review questions were based on the following frameworks:

- Intervention reviews—using population, intervention, comparator and outcome (PICO)
- Prognostic reviews—using population, presence or absence of a prognostic, risk or predictive factor and outcome (PPO)
- Epidemiologic reviews—using population, intervention and outcome (PIO)

These frameworks guided the development of review protocols, the literature searching process, and critical appraisal and synthesis of evidence. They also facilitated development of recommendations by the committee.

Full literature searches, critical appraisals and evidence reviews were completed for all review questions.

The review questions and evidence reviews corresponding to each question (or group of questions) are summarised below.

Table 1: Summary of review questions and index to evidence reviews

<table>
<thead>
<tr>
<th>Evidence review</th>
<th>Review question</th>
<th>Type of review</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] Yield MRI</td>
<td>What is the yield of relevant abnormalities detected by MRI in people with epilepsy?</td>
<td>Epidemiologic</td>
</tr>
<tr>
<td>[B] Yield CT</td>
<td>What is the yield of relevant abnormalities detected by CT in people with epilepsy?</td>
<td>Epidemiologic</td>
</tr>
<tr>
<td>[C] Genetic testing</td>
<td>What is the effectiveness of genetic testing in determining the aetiology of epilepsy?</td>
<td>Epidemiologic</td>
</tr>
<tr>
<td>[D] Antibody testing</td>
<td>In people with epilepsy, who should have antibody testing?</td>
<td>Prognostic¹</td>
</tr>
</tbody>
</table>
| [E] ASMs (monotherapy) in the treatment of GTC and focal onset seizures | • What antiseizure medications (monotherapy) are effective in the treatment of generalised tonic-clonic seizures?  
• What antiseizure medications (monotherapy) are effective in the treatment of focal onset seizures? | Intervention² |
<p>| [F] Antiseizure therapies (add-on) in the treatment of GTC | • What antiseizure therapies (add-on) are effective in the treatment of generalised tonic-clonic seizures? | Intervention² |</p>
<table>
<thead>
<tr>
<th>Evidence review</th>
<th>Review question</th>
<th>Type of review</th>
</tr>
</thead>
<tbody>
<tr>
<td>and focal onset seizures</td>
<td>• What antiseizure therapies (add-on) are effective in the treatment of focal onset seizures?</td>
<td></td>
</tr>
<tr>
<td>[G] Antiseizure therapies in the treatment of absence seizures</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of absence seizures?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[H] Antiseizure therapies in the treatment of myoclonic seizures</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of myoclonic seizures?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[I] Antiseizure therapies in the treatment of tonic or atonic seizures</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of tonic or atonic seizures?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[J] Antiseizure therapies in the treatment of IGEs</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of seizures in idiopathic generalised epilepsies (IGEs), including juvenile myoclonic epilepsy?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[K] Antiseizure therapies in the treatment of Dravet syndrome</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of seizures in Dravet syndrome?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[L] Antiseizure therapies in the treatment of LGS</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of seizures in Lennox-Gastaut syndrome (LGS)?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[M] Discontinuation of pharmacological treatment</td>
<td>What are the criteria for stopping antiseizure medications in people with epilepsy?</td>
<td>Prognostic</td>
</tr>
<tr>
<td>[N] Referral to specialist services</td>
<td>What are the criteria for referral to specialist services?</td>
<td>Prognostic</td>
</tr>
<tr>
<td>[O] Effectiveness of a nurse specialist</td>
<td>What is the effectiveness of a nurse specialist in the management of epilepsy?</td>
<td>Intervention²</td>
</tr>
<tr>
<td>[P] Antiseizure therapies in the treatment of infantile spasms</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of infantile spasms?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[Q] ASMs in the treatment of self-limited epilepsy with centrotemporal spikes</td>
<td>What antiseizure medications (monotherapy or add-on) are effective in the treatment of seizures in self-limited epilepsy with centrotemporal spikes?</td>
<td>Intervention</td>
</tr>
<tr>
<td>[R] Antiseizure therapies in the treatment of Doose syndrome</td>
<td>What antiseizure therapies (monotherapy or add-on) are effective in the treatment of seizures in myoclonic atonic epilepsy (Doose Syndrome)?</td>
<td>Intervention</td>
</tr>
</tbody>
</table>

¹Costing study undertaken
²Original health economic analysis conducted

The COMET database was searched for core outcome sets relevant to this guideline. Outcomes are in line with those described in the core outcome set for epilepsy.

Additional information related to development of the guideline is contained in:

Epilepsies in children, young people and adults: Methods (April 2022)
• Supplement 2 (Economics)
• Supplement 3 (Cost effectiveness of antiseizure therapies).
• Supplement 4 (NGA staff list).

Searching for evidence

Scoping search

During the scoping phase, searches were conducted for previous guidelines, economic evaluations, health technology assessments and systematic reviews. Searches of websites of organisations, institutional repositories and internet search engines were also undertaken for relevant policies and related documents, including grey literature.

Systematic literature search

Systematic literature searches were undertaken to identify published evidence relevant to each review question.

Databases were searched using subject headings, free-text terms and, where appropriate, study type filters. Where possible, searches were limited to retrieve studies published in English. All the searches were conducted in the following databases: Medical Literature Analysis and Retrieval System Online (MEDLINE) and MEDLINE-in-Process, Embase, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessments (HTA). For intervention questions related to nursing, EMCare and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were also searched.

Searches were run once for all reviews during development.

Searches for the following questions were updated between 31 March to 07 April 2021, around four weeks in advance of the final committee meeting.

C What is the effectiveness of genetic testing in determining the aetiology of epilepsy?

J What antiseizure therapies (monotherapy or add-on) are effective in the treatment of seizures in idiopathic generalised epilepsies (IGEs), including juvenile myoclonic epilepsy?

K What antiseizure therapies (monotherapy or add-on) are effective in the treatment of Dravet syndrome?

I What antiseizure therapies (monotherapy or add-on) are effective in the treatment of tonic or atonic seizures/drop attacks?

O What is the effectiveness of a nurse specialist in the management of epilepsy?

P What antiseizure therapies (monotherapy or add-on) are effective in the treatment of infantile spasms?
Q What antiseizure medications (monotherapy or add-on) are effective in the treatment of seizures in self-limited epilepsy with centrotemporal spikes?

R What antiseizure therapies (monotherapy or add-on) are effective in the treatment of seizures in myoclonic atonic epilepsy (Doose syndrome)?

Details of the search strategies, including the study-design filters used and databases searched, are provided in appendix B of each evidence review.

In addition, search updates for the following questions were undertaken on 03 February 2021, earlier than for other topics, due to the more complex nature of the analyses for these topics.

E What antiseizure medications (monotherapy) are effective in the treatment of generalised tonic-clonic seizures and focal seizures?

F What antiseizure therapies (add-on) are effective in the treatment of generalised tonic-clonic seizures and focal seizures?

**Economic systematic literature search**

Systematic literature searches were also undertaken to identify published economic evidence. Databases were searched using subject headings, free-text terms and, where appropriate, an economic evaluations search filter.

A single search, using the population search terms used in the evidence reviews, was conducted to identify economic evidence in the NHS Economic Evaluation Database (NHS EED) and the HTA. Another single search, using the population search terms used in the evidence reviews combined with an economic evaluations search filter, was conducted in MEDLINE and MEDLINE-in-Process, and Embase. Where possible, searches were limited to studies published in English.

The economic literature searches were updated on 31 March 2021, four weeks in advance of the final committee meeting before consultation on the draft guideline.

Details of the search strategies, including the study-design filter used and databases searched, are provided in Supplement 2 (Health economics).

**Quality assurance**

Search strategies were quality assured by cross-checking reference lists of relevant studies, analysing search strategies from published systematic reviews and asking members of the committee to highlight key studies. The principal search strategies for each search were also quality assured by a second information scientist using an adaptation of the PRESS 2015 Guideline Evidence-Based Checklist (McGowan 2016). In addition, all publications highlighted by stakeholders at the time of the consultation on the draft scope were considered for inclusion.

**Reviewing research evidence**

**Systematic review process**

The evidence was reviewed in accordance with the following approach.
• Potentially relevant articles were identified from the search results for each review question by screening titles and abstracts. Full-text copies of the articles were then obtained.

• Full-text articles were reviewed against pre-specified inclusion and exclusion criteria in the review protocol (see appendix A of each evidence review).

• Key information was extracted from each article on study methods and results, in accordance with factors specified in the review protocol. The information was presented in a summary table in the corresponding evidence review and in a more detailed evidence table (see appendix D of each evidence review).

• Included studies were critically appraised using an appropriate checklist as specified in Developing NICE guidelines: the manual. Further detail on appraisal of the evidence is provided below.

• Summaries of evidence by outcome were presented in the corresponding evidence review and discussed by the committee.

Review questions informing network meta-analyses (NMA), selected as high priorities for economic analysis (and those selected as medium priorities and where economic analysis could influence recommendations) and complex review questions were subject to dual screening and study selection through a 10% random sample of articles. Any discrepancies were resolved by discussion between the first and second reviewers or by reference to a third (senior) reviewer. For the remaining review questions, internal (NGA) quality assurance processes included consideration of the outcomes of screening, study selection and data extraction and the committee reviewed the results of study selection and data extraction. The review protocol for each question specifies whether dual screening and study selection was undertaken for that particular question.

Drafts of all evidence reviews were quality assured by a senior reviewer.

**Type of studies and inclusion/exclusion criteria**

Inclusion and exclusion of studies was based on criteria specified in the corresponding review protocol.

Systematic reviews with meta-analyses were considered to be the highest quality evidence that could be selected for inclusion.

For intervention reviews, randomised controlled trials (RCTs) were prioritised for inclusion because they are considered to be the most robust type of study design that could produce an unbiased estimate of intervention effects. Where there was limited evidence from RCTs, non-randomised studies (NRS) were considered for inclusion.

For prognostic reviews, prospective and retrospective cohort studies were considered for inclusion. Studies that included multivariable analysis were prioritised.

For epidemiological reviews, prospective and retrospective cohort studies were considered for inclusion.

The committee was consulted about any uncertainty regarding inclusion or exclusion of studies. A list of excluded studies for each review question, including reasons for exclusion is presented in appendix K of the corresponding evidence review.
Narrative reviews, posters, letters, editorials, comment articles, unpublished studies and studies published in languages other than English were excluded. Conference abstracts were not considered for inclusion because conference abstracts typically do not have sufficient information to allow for full critical appraisal.

**Methods of combining evidence**

When planning reviews (through preparation of protocols), the following approaches for data synthesis were discussed and agreed with the committee.

**Data synthesis for intervention studies**

**Pairwise meta-analysis**

Meta-analysis to pool results from comparative intervention studies was conducted where possible using Cochrane Review Manager (RevMan5) software.

For dichotomous outcomes, such as reduction of seizure frequency >50%, the Mantel–Haenszel method with a fixed effect model was used to calculate risk ratios (RRs). For all outcomes with zero events in both arms the risk difference was presented. For outcomes in which the majority of studies had low event rates (<1%), Peto odds ratios (PORs) were calculated as this method performs well when events are rare (Bradburn 2007).

For continuous outcomes, measures of central tendency (mean) and variation (standard deviation; SD) are required for meta-analysis. Data for continuous outcomes, such as quality of life, were meta-analysed using an inverse-variance method for pooling weighted mean differences (WMDs). Where SDs were not reported for each intervention group, the standard error (SE) of the mean difference was calculated from other reported statistics (p values or 95% confidence intervals; CIs) and then meta-analysis was conducted as described above.

If a study reported only the summary statistic and 95% CI, the generic-inverse variance method was used to enter data into RevMan5. If the control event rate was reported, this was used to generate the absolute risk difference in GRADEpro. If multivariable analysis was used to derive the summary statistic but no adjusted control event rate was reported, no absolute risk difference was calculated.

When evidence was based on studies that reported descriptive data or medians with interquartile ranges or p values, this information was included in the corresponding GRADE tables (see below) without calculating relative or absolute effects. Consequently, certain aspects of quality assessment such as imprecision of the effect estimate could not be assessed as per standard methods for this type of evidence and subjective ratings or ratings based on sample size cut-offs were considered instead.

For some reviews, evidence was either stratified from the outset or separated into subgroups when heterogeneity was encountered. The stratifications and potential subgroups were pre-defined at the protocol stage (see the protocols for each review for further detail). Where evidence was stratified or subgrouped, the committee considered on a case by case basis if separate recommendations should be made for distinct groups. Separate recommendations may be made where there is evidence of a differential effect of interventions in distinct groups. If there is a lack of
evidence in one group, the committee considered, based on their experience, whether it was reasonable to extrapolate and assume the interventions will have similar effects in that group compared with others.

When meta-analysis was undertaken, the results were presented visually using forest plots generated using RevMan5 (see appendix E of relevant evidence reviews).

**Network meta-analysis**

As is the case for ordinary pairwise meta-analysis, network meta-analysis (NMA) may be conducted using either fixed or random effect models. A fixed effect model typically assumes that there is no variation in relative effects across trials for a particular pairwise comparison and any observed differences are solely due to chance. For a random effects model, it is assumed that the relative effects are different in each trial but that they are from a single common distribution. The variance reflecting heterogeneity is often assumed to be constant across trials.

In a Bayesian analysis, for each parameter the evidence distribution is weighted by a distribution of prior beliefs. The Markov chain Monte Carlo (MCMC) algorithm was used to generate a sequence of samples from a joint posterior distribution of 2 or more random variables and is particularly well adapted to sampling the treatment effects (known as a posterior distribution) of a Bayesian network. A prior distribution was used to maximise the weighting given to the data and to generate the posterior distribution of the results.

For the analyses, a series of burn-in simulations were run to allow the posterior distributions to converge and then further simulations were run to produce the posterior outputs. Convergence was assessed by examining the history, autocorrelation and Brooks-Gelman-Rubin plots.

Goodness-of-fit of the model was also estimated by using the posterior mean of the sum of the deviance contributions for each item by calculating the residual deviance and deviance information criteria (DIC). If the residual deviance was close to the number of unconstrained data points (the number of trial arms in the analysis) then the model was explaining the data at a satisfactory level. The choice of a fixed effect or random effects model can be made by comparing their goodness-of-fit to the data. Treatment specific posterior effects were generated for every possible pair of comparisons by combining direct and indirect evidence in each network. The probability that each treatment is best, based on the proportion of Markov chain iterations in which the treatment effect for an intervention is ranked best, second best and so forth. This was calculated by taking the treatment effect of each intervention compared to the reference treatment and counting the proportion of simulations of the Markov chain in which each intervention had the highest treatment effect.


Where there was a high level of heterogeneity, sub-group analysis, or the inclusion of covariates was undertaken to adjust for unobserved effect modifiers. The goodness-of-fit of the model was compared to unadjusted models using the same methodology as for comparing fixed and random-effects models. The ‘bias adjustment’ code available from NICE Decision Support Unit (DSU) technical support document
number 3 http://nicedsu.org.uk/technical-support-documents/evidence-synthesis-tsd-series/ was adapted.

To determine if there is evidence of inconsistency, the selected consistency model (fixed or random effects) was compared to an “inconsistency”, or unrelated mean effects, model. We performed further checks for evidence of inconsistency through node-splitting.

For further description of the model used, specific methods, outcomes and the results of the NMA please see the evidence reports E and F.

The quality assurance of all the NMA work was undertaken by the NICE Guidelines Technical Support Unit, University of Bristol (TSU).

Handling of cluster randomised trials

Where cluster randomised trials were included in evidence reviews they were analysed to minimise the potential for unit-of-analysis error. If studies reported contrast level outcomes (for example risk ratios, mean differences) that appeared to have been calculated taking into account the cluster study design, these were preferentially extracted over raw data (for example counts of events in each arm or mean and standard deviation of each arm). However, if raw data was used, a design effect adjustment was made (Higgins 2020) using an appropriate estimate of the intracluster correlation coefficient, details on the calculation are provided in the relevant evidence reviews. Meta-analyses were undertaken where appropriate using the same methodology as for individually randomised trials described in the pairwise meta-analysis section.

Data synthesis for prognostic reviews

Odd ratios (ORs) or hazard ratios (HRs) with 95% CIs reported in published studies were extracted by the NGA technical team to examine relationships between risk factors and outcomes of interest. Ideally analyses would have adjusted for key confounders (such as age or sex) to be considered for inclusion. Recognising variation across studies in terms of populations, risk factors, outcomes and statistical analysis methods (including adjustments for confounding factors), prognostic data were not meta-analysed, but results from individual studies were presented in the evidence reviews.

Data synthesis for epidemiologic reviews

Proportions were obtained by dividing the number of people with epilepsy related abnormalities (in evidence reports A and B) and the number of people with pathogenic or likely pathogenic genetic abnormalities (in evidence report C) by the total number of people who received the relevant intervention. Meta-analysis of proportions was performed with R studio version 4.0.3 and the meta package. Because of expected heterogeneity among study populations and the interventions they received, a random-effects model was considered a priori.
Appraising the quality of evidence

**Intervention studies**

*Pairwise meta-analysis*

**GRADE methodology for intervention reviews**

For intervention reviews, the evidence for outcomes from included RCTs and comparative non-randomised studies was evaluated and presented using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology developed by the international GRADE working group. When GRADE was applied, software developed by the GRADE working group (GRADEpro) was used to assess the quality of each outcome, taking account of individual study quality factors and any meta-analysis results. Results were presented in GRADE profiles (GRADE tables).

The selection of outcomes for each review question was agreed during development of the associated review protocol in discussion with the committee. The evidence for each outcome was examined separately for the quality elements summarised in Table 2. Criteria considered in the rating of these elements are discussed below. Each element was graded using the quality ratings summarised in Table 3. Footnotes to GRADE tables were used to record reasons for grading a particular quality element as having a ‘serious’ or ‘very serious’ quality issue. The ratings for each component were combined to obtain an overall assessment of quality for each outcome as described in Table 4.

The initial quality rating was based on the study design: RCTs and NRS assessed by ROBINS-I start as ‘high’ quality evidence, other non-randomised studies start as ‘low’ quality evidence. The rating was then modified according to the assessment of each quality element (Table 2). Each quality element considered to have a ‘serious’ or ‘very serious’ quality issue was downgraded by 1 or 2 levels respectively (for example, evidence starting as ‘high’ quality was downgraded to ‘moderate’ or ‘low’ quality). In addition, there was a possibility to upgrade evidence from non-randomised studies (provided the evidence for that outcome had not previously been downgraded) if there was a large magnitude of effect, a dose–response gradient, or if all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results showed no effect.

**Table 2: Summary of quality elements in GRADE for intervention reviews**

<table>
<thead>
<tr>
<th>Quality element</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of bias (‘Study limitations’)</td>
<td>This refers to limitations in study design or implementation that reduce the internal validity of the evidence</td>
</tr>
<tr>
<td>Inconsistency</td>
<td>This refers to unexplained heterogeneity in the results</td>
</tr>
<tr>
<td>Indirectness</td>
<td>This refers to differences in study populations, interventions, comparators or outcomes between the available evidence and inclusion criteria specified in the review protocol</td>
</tr>
<tr>
<td>Quality element</td>
<td>Description</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Imprecision</td>
<td>This occurs when a study has few participants or few events of interest, resulting in wide confidence intervals that cross minimally important thresholds</td>
</tr>
<tr>
<td>Publication bias</td>
<td>This refers to systematic under- or over-estimation of the underlying benefit or harm resulting from selective publication of study results</td>
</tr>
</tbody>
</table>

**Table 3: GRADE quality ratings (by quality element)**

<table>
<thead>
<tr>
<th>Quality issues</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>None or not serious</td>
<td>No serious issues with the evidence for the quality element under consideration</td>
</tr>
<tr>
<td>Serious</td>
<td>Issues with the evidence sufficient to downgrade by 1 level for the quality element under consideration</td>
</tr>
<tr>
<td>Very serious</td>
<td>Issues with the evidence sufficient to downgrade by 2 levels for the quality element under consideration</td>
</tr>
</tbody>
</table>

**Table 4: Overall quality of the evidence in GRADE (by outcome)**

<table>
<thead>
<tr>
<th>Overall quality grading</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Further research is very unlikely to change the level of confidence in the estimate of effect</td>
</tr>
<tr>
<td>Moderate</td>
<td>Further research is likely to have an important impact on the level of confidence in the estimate of effect and may change the estimate</td>
</tr>
<tr>
<td>Low</td>
<td>Further research is very likely to have an important impact on the level of confidence in the estimate of effect and is likely to change the estimate</td>
</tr>
<tr>
<td>Very low</td>
<td>The estimate of effect is very uncertain</td>
</tr>
</tbody>
</table>

**Assessing risk of bias in intervention reviews**

Bias is a systematic error, or consistent deviation from the truth in results obtained. When a risk of bias is present the true effect can be either under- or over-estimated.

Risk of bias in RCTs was assessed using the Cochrane risk of bias v2 tool (see Appendix H in Developing NICE guidelines: the manual)

The Cochrane risk of bias tool assesses the following possible sources of bias:
- Bias arising from the randomisation process
- Bias due to deviations from intended interventions
- Bias due to missing outcome data
- Bias in measurement of the outcome
- Bias in selection of the reported results

A study with a poor methodological design does not automatically imply high risk of bias; the bias is considered individually for each outcome and it is assessed whether the chosen design and methodology will impact on the estimation of the intervention effect.

Epilepsies in children, young people and adults: Methods (April 2022)
More details about the Cochrane risk of bias tool can be found in Section 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2020).

For systematic reviews of RCTs the AMSTAR checklist was used and for systematic reviews of other study types the ROBIS checklist was used (see appendix H in Developing NICE guidelines: the manual).

For non-randomised studies the ROBINS-I checklist was used (see appendix H in Developing NICE guidelines: the manual).

**Assessing inconsistency in intervention reviews**

Inconsistency refers to unexplained heterogeneity in results of meta-analysis. When estimates of treatment effect vary widely across studies (that is, there is heterogeneity or variability in results), this suggests true differences in underlying effects. Inconsistency is, thus, only truly applicable when statistical meta-analysis is conducted (that is, results from different studies are pooled). When outcomes were derived from a single study the rating ‘no serious inconsistency’ was used when assessing this domain, as per GRADE methodology (Santesso 2016).

Inconsistency was assessed visually by inspecting forest plots and observing whether there was considerable heterogeneity in the results of the meta-analysis (for example if the point estimates of the individual studies consistently showed benefits or harms). This was supported by calculating the I-squared statistic for the meta-analysis with an I-squared value of more than 50% indicating serious heterogeneity, and more than 75% indicating very serious heterogeneity. When serious or very serious heterogeneity was observed, possible reasons were explored and subgroup analyses were performed as pre-specified in the review protocol where possible.

When considerable heterogeneity was present, the meta-analysis was re-run using the Der-Simonian and Laird method with a random effects model and this was used for the final analysis.

When no plausible explanation for the serious or very serious heterogeneity could be found, the quality of the evidence was downgraded in GRADE for inconsistency.

**Assessing indirectness in intervention reviews**

Directness refers to the extent to which populations, interventions, comparisons and outcomes reported in the evidence are similar to those defined in the inclusion criteria for the review and was assessed by comparing the PICO elements in the studies to the PICO defined in the review protocol. Indirectness is important when such differences are expected to contribute to a difference in effect size, or may affect the balance of benefits and harms considered for an intervention.

**Assessing imprecision and importance in intervention reviews**

Imprecision in GRADE methodology refers to uncertainty around the effect estimate and whether or not there is an important difference between interventions (that is, whether the evidence clearly supports a particular recommendation or appears to be consistent with several candidate recommendations). Therefore, imprecision differs from other aspects of evidence quality because it is not concerned with whether the point estimate is accurate or correct (has internal or external validity). Instead, it is concerned with uncertainty about what the point estimate actually represents. This uncertainty is reflected in the width of the 95% CI.
The 95% CI is defined as the range of values within which the population value will fall on 95% of repeated samples, were the procedure to be repeated. The larger the study, the smaller the 95% CI will be and the more certain the effect estimate.

Imprecision was assessed in the guideline evidence reviews by considering whether the width of the 95% CI of the effect estimate was relevant to decision making, considering each outcome independently. This is illustrated in Figure 1, which considers a positive outcome for the comparison of two treatments. Three decision-making zones can be differentiated, bounded by the thresholds for minimal importance (minimally important differences; MIDs) for benefit and harm.

When the CI of the effect estimate is wholly contained in 1 of the 3 zones there is no uncertainty about the size and direction of effect, therefore, the effect estimate is considered precise; that is, there is no imprecision.

When the CI crosses 2 zones, it is uncertain in which zone the true value of the effect estimate lies and therefore there is uncertainty over which decision to make. The 95% CI is consistent with 2 possible decisions, therefore, the effect estimate is considered to be imprecise in the GRADE analysis and the evidence is downgraded by 1 level (‘serious imprecision’).

When the 95% CI crosses all 3 zones, the effect estimate is considered to be very imprecise because the CI is consistent with 3 possible decisions and there is therefore a considerable lack of confidence in the results. The evidence is therefore downgraded by 2 levels in the GRADE analysis (‘very serious imprecision’).

Implicitly, assessing whether a 95% CI is in, or partially in, an important zone, requires the guideline committee to estimate an MID or to say whether they would make different decisions for the 2 confidence limits.

**Figure 1: Assessment of imprecision and importance in intervention reviews using GRADE**

![Assessment of imprecision and importance in intervention reviews using GRADE](image)

**MID:** minimally important difference

**Defining minimally important differences for intervention reviews**

The committee was asked whether there were any recognised or acceptable MIDs in the published literature and community relevant to the review questions under

Epilepsies in children, young people and adults: Methods (April 2022)
consideration. The committee was not aware of any MIDs that could be used for the guideline.

In the absence of published or accepted MIDs, the committee agreed to use the GRADE default MIDs to assess imprecision. For dichotomous outcomes minimally important thresholds for a RR of 0.8 and 1.25 respectively were used as default MIDs in the guideline. The committee also chose to use 0.8 and 1.25 as the MIDs for ORs & HRs in the absence of published or accepted MIDs. ORs were predominantly used in the guideline when Peto OR were indicated due to low event rates, at low event rates OR are mathematically similar to RR making the extrapolation appropriate. While no default MIDs exist for HR, the committee agreed for consistency to continue to use 0.8 and 1.25 for these outcomes.

If risk difference was used for meta-analysis, for example if the majority of studies had zero events in either arm, imprecision was assessed based on absolute effect ranges using 10 more per 1000 and 10 fewer per 1000 as the cut-offs for serious and very serious imprecision. The committee used these numbers based on commonly used optimal information size thresholds.

The same thresholds were used as default MIDs in the guideline for all dichotomous outcomes considered in intervention evidence reviews. For continuous outcomes default MIDs are equal to half the median SD of the control groups at baseline (or at follow-up if the SD is not available a baseline).

In this guideline by default a finding was considered important when the point estimate lay outside the MID boundaries and the 95% CI did not cross the line of no effect.

Assessing publication bias in intervention reviews

Where 10 or more studies were included as part of a single meta-analysis, a funnel plot was produced to graphically assess the potential for publication bias. However no enough studies were included in a single meta-analysis, therefore the committee subjectively assessed the likelihood of publication bias based on factors such as the proportion of trials funded by industry and the propensity for publication bias in the topic area.

Network meta-analysis

For the NMAs, quality was assessed by looking at risk of bias across the included evidence using the Cochrane Risk of Bias Tool for Randomized Controlled Trials, as well as heterogeneity and consistency (also called incoherence).

The following limits of the upper 95% credible interval (Crl) for between-study standard deviation were used to assess heterogeneity for NMAs in which a random effects model was used:

- less than 0.3 – low heterogeneity
- 0.3 to 0.6 – moderate heterogeneity
- more than 0.6 to 0.9 – high heterogeneity
- more than 0.9 to 1.2 – very high heterogeneity
The consistency between direct and indirect evidence can be assessed in closed treatment loops within the network. These closed treatment loops are regions within a network where direct evidence is available on at least 3 different treatments that form a closed ‘circuit’ of treatment comparisons (for example, A versus B, B versus C, C versus A). If closed treatment loops existed then discrepancies between direct and indirect evidence was assessed.

To determine if there is evidence of inconsistency, the selected consistency model (fixed or random effects) was compared to an “inconsistency”, or unrelated mean effects, model. The latter is equivalent to having separate, unrelated, meta-analyses for every pairwise contrast, with a common variance parameter assumed in the case of random effects models. Further checks for evidence of inconsistency either through Bucher's method or node-splitting were undertaken. Bucher's method compares the direct and indirect estimates for a contrast in a loop (e.g., A-B-C) where the direct estimate of contrast B vs. C is compared to its corresponding indirect estimate, which is informed from the direct estimates of the other contrasts in the loop (A vs. B and A vs. C). This method was used to assess consistency in networks, where there was a single loop and the network contained sparse evidence with zero events, limiting the stability of the results of more sophisticated methods such as the node-splitting method. The node-splitting method allowed the direct and indirect evidence contributing to an estimate of a relative effect to be split and compared. The consistency checks were undertaken by the TSU.

For fixed-effect NMAs that did not model heterogeneity, or for networks in which inconsistency could not be assessed as no closed treatment loops existed, these criteria were not considered to impact the quality of evidence.

### Prognostic studies

**Adapted GRADE methodology for prognostic reviews**

For prognostic reviews with evidence from comparative studies an adapted GRADE approach was used. As noted above, GRADE methodology is designed for intervention reviews but the quality assessment elements were adapted for prognostic reviews.

The evidence for each outcome in the prognostic reviews was examined separately for the quality elements listed and defined in Table 5. The criteria considered in the rating of these elements are discussed below. Each element was graded using the quality levels summarised in Table 3. Footnotes to GRADE tables were used to record reasons for grading a particular quality element as having ‘serious’ or ‘very serious’ quality issues. The ratings for each component were combined to obtain an overall assessment of quality for each outcome as described in Table 4.

<table>
<thead>
<tr>
<th>Quality element</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of bias (‘Study limitations’)</td>
<td>Limitations in study design and implementation may bias estimates and interpretation of the effect of the prognostic/risk factor. High risk of bias for the majority of the evidence reduces confidence in the estimated effect. Prognostic studies are not</td>
</tr>
<tr>
<td>Quality element</td>
<td>Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>usually randomised and therefore would not be downgraded for study design from the outset (they start as high quality)</td>
<td></td>
</tr>
<tr>
<td>Inconsistency</td>
<td>This refers to unexplained heterogeneity between studies looking at the same prognostic/risk factor, resulting in wide variability in estimates of association (such as RRs or ORs), with little or no overlap in confidence intervals</td>
</tr>
<tr>
<td>Indirectness</td>
<td>This refers to any departure from inclusion criteria listed in the review protocol (such as differences in study populations or prognostic/risk factors), that may affect the generalisability of results</td>
</tr>
<tr>
<td>Imprecision</td>
<td>This occurs when a study has relatively few participants and also when the number of participants is too small for a multivariable analysis (as a rule of thumb, 10 participants are needed per variable). Imprecision was assessed by considering the confidence interval in relation to the point estimate for each outcome reported in the included studies</td>
</tr>
</tbody>
</table>

RR: relative risk; OR: odds ratio

**Assessing risk of bias in prognostic reviews**

The Quality in Prognosis Studies (QUIPS) tool developed by Hayden 2013 was used to assess risk of bias in studies included in prognostic reviews (see Appendix H in the Developing NICE guidelines: the manual). The risk of bias in each study was determined by assessing the following domains:

- selection bias
- attrition bias
- prognostic factor bias
- outcome measurement bias
- control for confounders
- appropriate statistical analysis.

**Assessing inconsistency in prognostic reviews**

Where multiple results were deemed appropriate to meta-analyse (that is, there was sufficient similarity between risk factor and outcome under investigation) inconsistency was assessed by visually inspecting forest plots and observing whether there was considerable heterogeneity in the results of the meta-analysis. This was assessed by calculating the I-squared statistic for the meta-analysis with an I-squared value of more than 50% indicating serious heterogeneity, and more than 75% indicating very serious heterogeneity. When serious or very serious heterogeneity was observed, possible reasons were explored and subgroup analyses were performed as pre-specified in the review protocol where possible.

When no plausible explanation for the heterogeneity could be found, the quality of the evidence was downgraded in GRADE for inconsistency.

**Assessing indirectness in prognostic reviews**

Indirectness in prognostic reviews was assessed by comparing the populations, prognostic factors and outcomes in the evidence to those defined in the review protocol.
Assessing imprecision and importance in prognostic reviews

Prognostic studies may have a variety of purposes, for example, establishing typical prognosis in a broad population, establishing the effect of patient characteristics on prognosis, and developing a prognostic model. While by convention MIDs relate to intervention effects, the committee agreed to use GRADE default MIDs for intervention studies as a starting point from which to assess imprecision. The committee also agreed to use statistical significance to indicate clinical importance because the aim of the review is to inform people with epilepsy about factors that may lead to seizure recurrence rather than recommend one intervention or another.

Epidemiologic reviews

Adapted GRADE methodology for epidemiologic reviews

For epidemiologic reviews, the evidence for proportions from included single-arm observational studies was evaluated and presented using an adapted GRADE approach.

The evidence for each proportion was examined separately for the quality elements listed and defined in Table 6. The criteria considered in the rating of these elements are discussed below. Each element was graded using quality levels summarised in Table 3. Footnotes to GRADE tables were used to record reasons for grading a particular quality element as having ‘serious’ or ‘very serious’ quality issues. The ratings for each component were combined to obtain an overall assessment of quality for each outcome as described in Table 4.

Table 6: Adaptation of GRADE quality elements for epidemiologic reviews

<table>
<thead>
<tr>
<th>Quality element</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of bias (‘Study limitations’)</td>
<td>Limitations in study design and implementation may bias estimates and interpretation of the effect of the proportion. High risk of bias for the majority of the evidence reduces confidence in the estimated proportion.</td>
</tr>
<tr>
<td>Inconsistency</td>
<td>This refers to unexplained heterogeneity in the results</td>
</tr>
<tr>
<td>Indirectness</td>
<td>This refers to differences in study populations, interventions or outcome between the available evidence and inclusion criteria specified in the review protocol</td>
</tr>
<tr>
<td>Imprecision</td>
<td>This occurs when a study has relatively few participants and the probability of a correct estimation is low</td>
</tr>
</tbody>
</table>

Assessing risk of bias in epidemiologic reviews

The Center for Evidence-Based Management (CEBMA) checklist tool was used to assess risk of bias in studies included in the epidemiologic reviews (see Appendix H in the Developing NICE guidelines: the manual). The risk of bias in each study was determined by assessing the following domains:

- selection bias
- attrition bias
- outcome measurement bias
- appropriate statistical analysis.
Assessing inconsistency in epidemiologic reviews

Where multiple proportions were deemed appropriate to meta-analyse (that is, there was sufficient similarity with the intervention and outcome assessed) inconsistency was assessed by visually inspecting forest plots and observing whether there was considerable heterogeneity in the results of the meta-analysis. This was assessed by calculating the I-squared statistic for the meta-analysis with an I-squared value of more than 50% indicating serious heterogeneity, and more than 75% indicating very serious heterogeneity. When serious or very serious heterogeneity was observed, possible reasons were explored and subgroup analyses were performed as pre-specified in the review protocol where possible.

When no plausible explanation for the heterogeneity could be found, the quality of the evidence was downgraded in GRADE for inconsistency.

Assessing indirectness in epidemiologic reviews

Indirectness in epidemiologic reviews was assessed by comparing the populations, interventions and outcomes in the evidence to those defined in the review protocol.

Assessing imprecision and importance in prognostic reviews

Imprecision was assessed based on sample size using 150 and 300 as cut-offs for very serious and serious imprecision respectively. The committee used these numbers based on commonly used optimal information size thresholds. The committee agreed that >1% yield was considered important.

Reviewing economic evidence

Titles and abstracts of articles identified through the economic literature searches were independently assessed for inclusion using the predefined inclusion and exclusion criteria

Inclusion and exclusion criteria for systematic reviews of economic evaluations

Inclusion and exclusion criteria

- If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it was included in the guideline. A health economic evidence table was completed and it was included in the health economic evidence profile.
- If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it was excluded from the guideline. If it is excluded then a health economic evidence table was not be completed and it was not be included in the health economic evidence profile.
- If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then discretion was used over whether it should be included.

Where there is discretion

The health economist made a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim was to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting.
The health economist was guided by the following hierarchies.

**Setting:**
- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA were excluded before being assessed for applicability and methodological limitations.

**Health economic study type:**
- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies were excluded before being assessed for applicability and methodological limitations.

**Year of analysis:**
- The more recent the study, the more applicable it will be.
- Studies published in 2005 or later (including any such studies included in the previous guideline(s)) but that depend on unit costs and resource data entirely or predominantly from before 2005 was rated as ‘Not applicable’.
- Studies published before 2005 (including any such studies included in the previous guideline(s)) was excluded before being assessed for applicability and methodological limitations.

**Appraising the quality of economic evidence**

The quality of economic evidence was assessed using the economic evaluations checklist specified in Developing NICE guidelines: the manual.

**Economic modelling**

The aims of the economic input to the guideline were to inform the guideline committee of potential economic issues to ensure that recommendations represented a cost effective use of healthcare resources. Economic evaluations aim to integrate data on healthcare benefits (ideally in terms of quality-adjusted life-years; QALYs) with the costs of different options. In addition, the economic input aimed to identify areas of high resource impact; these are recommendations which (while cost effective) might have a large impact on Clinical Commissioning Group or Trust finances and so need special attention.

The guideline committee prioritised the following review questions for economic modelling where it was thought that economic considerations would be particularly important in formulating recommendations:
- E What antiseizure medications (monotherapy) are effective in the treatment of generalised tonic-clonic seizures and focal seizures
• F What antiseizure therapies (add-on) are effective in the treatment of generalised tonic-clonic seizures and focal seizures?
• O What is the effectiveness of a nurse specialist in the management of epilepsy?

A further costing study was undertaken for the following topics:
• C What is the effectiveness of genetic testing in determining the aetiology of epilepsy?

The methods and results of the de novo economic analyses are reported in Appendix I of the relevant evidence reports. When new economic analysis was not prioritised, the committee made a qualitative judgement regarding cost effectiveness by considering expected differences in resource and cost use between options, alongside clinical effectiveness evidence identified from the clinical evidence review.

Cost effectiveness criteria

NICE’s report Social value judgements: principles for the development of NICE guidance sets out the principles that committees should consider when judging whether an intervention offers good value for money. In general, an intervention was considered to be cost effective if any of the following criteria applied (provided that the estimate was considered plausible):
• the intervention dominated other relevant strategies (that is, it was both less costly in terms of resource use and more effective compared with all the other relevant alternative strategies)
• the intervention cost less than £20,000 per QALY gained compared with the next best strategy
• the intervention provided important benefits at an acceptable additional cost when compared with the next best strategy.

The committee’s considerations of cost effectiveness are discussed explicitly under the heading ‘Cost effectiveness and resource use’ in the relevant evidence reviews.

Developing recommendations

Guideline recommendations

Recommendations were drafted on the basis of the committee’s interpretation of the available evidence, taking account of the balance of benefits, harms and costs between different courses of action. When effectiveness and economic evidence was of poor quality, conflicting or absent, the committee drafted recommendations based on their expert opinion. The considerations for making consensus-based recommendations include the balance between potential benefits and harms, the economic costs or implications compared with the economic benefits, current practices, recommendations made in other relevant guidelines, person’s preferences and equality issues.

The main considerations specific to each recommendation are outlined under the heading ‘The committee’s discussion of the evidence’ within each evidence review.
For further details refer to Developing NICE guidelines: the manual.

Research recommendations

When areas were identified for which evidence was lacking, the committee considered making recommendations for future research. For further details refer to Developing NICE guidelines: the manual and NICE’s Research recommendations process and methods guide and the Research Recommendations Process and Methods guide.

Validation process

This guideline was subject to a 6-week public consultation and feedback process. All comments received from registered stakeholders were responded to in writing and posted on the NICE website at publication. For further details refer to Developing NICE guidelines: the manual.

Updating the guideline

Following publication, NICE will undertake a surveillance review to determine whether the evidence base has progressed sufficiently to consider altering the guideline recommendations and warrant an update. For further details refer to Developing NICE guidelines: the manual.

Funding

The NGA was commissioned by NICE to develop this guideline.
References

Bradburn 2007

Dixon-Woods 2005

Hayden 2013

Higgins 2020

Lewin 2015

McGowan 2016

NICE 2018

Santesso 2016